Search
Letrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigationalLetrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Van-letrozoleSevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approvedSevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. … [A249910] Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.[A249885]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesPhenolsulfonphthalein
go.drugbank.com/drugs/DB13212ExperimentalPhenolsulfonphthalein or otherwise called phenol red is a pH indicator commonly used in cell biology laboratories. … Phenolsulfonphthalein is being investigated for use clinically due to its weak estrogen mimicking actions [A174964].
Nefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnIts sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. … Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb.
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsTrihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.
Products: Nu-trihexyphenidylEnasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalEnasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) … This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesEniluracil
go.drugbank.com/drugs/DB03516InvestigationalEniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available. … Eniluracil has received Orphan Drug status from the FDA for the treatment of hepatocellular cancer in combination with fluoropyrimidines (including 5-FU).
Shark liver oil
go.drugbank.com/drugs/DB11088ApprovedShark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. … The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity.
Mixtures: DG Health HemorrhoidalCelecoxib
go.drugbank.com/drugs/DB00482ApprovedInvestigationalCelecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptom...
Synonyms: p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamideCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesTegtociclib
go.drugbank.com/drugs/DB21635InvestigationalTegtociclib has a monoisotopic molecular weight of 404.22 Da. … Tegtociclib is under investigation in clinical trial NCT05262400 (A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid